Guideline for clinical use of thalidomide for management of erythema nodosum leprosum in Japan
- 1 January 2017
- journal article
- Published by Japanese Leprosy Association in JAPANESE JOURNAL OF LEPROSY
- Vol. 86 (2) , 91-100
Abstract
Treatment of erythema nodosum leprosum (ENL, type 2 lepra reaction) with thalidomide is an effective alternative to steroid therapy, but Ministry of Health, Labour and Welfare (Japan) has only approved thalidomide (Thaled® Capsule, Fujimoto Pharmaceutical Corp.) for the treatment of multiple myeloma under the Thalidomide Education and Risk Management System (TERMS®) 2008. Then thalidomide was approved for ENL in 2012 by Ministry of Health, Labour and Welfare. Use of thalidomide for patients with ENL has already been established by various studies in other countries, but limited experience in Japan has hindered application of this medication to domestic patients. This led us to devise a guideline on the usage of thalidomide to treat ENL in Japan. Based on TERMS®, we suggest that administration of thalidomide for ENL should be started at 50-100mg/day p. o. before going to bed and then the dose should be adjusted according to the patient’s symptoms, while not exceeding the maximum recommended dose of 300mg/day.Keywords
This publication has 18 references indexed in Scilit:
- Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: A randomized studyAustralasian Journal of Dermatology, 2009
- Interventions for erythema nodosum leprosumCochrane Database of Systematic Reviews, 2009
- Peripheral Neuropathy Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership BoardClinical Journal of Oncology Nursing, 2008
- Clinicopathologic challengeInternational Journal of Dermatology, 2007
- Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosyBrazilian Journal of Medical and Biological Research, 2007
- Thalidomide in cancerBiomedicine & Pharmacotherapy, 2002
- Leprosy reactions.JAPANESE JOURNAL OF LEPROSY, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum LeprosumThe Journal of Infectious Diseases, 1993
- Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactionsClinical Immunology and Immunopathology, 1992